<DOC>
	<DOCNO>NCT00003087</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Radiation therapy use high-energy x-rays damage tumor cell . Combining one drug radiation therapy surgery may kill tumor cell . PURPOSE : Phase II trial study effectiveness combination chemotherapy , radiation therapy , surgery treating patient cancer esophagus surgically remove .</brief_summary>
	<brief_title>Combination Chemotherapy , Radiation Therapy Surgery Treating Patients With Cancer Esophagus</brief_title>
	<detailed_description>OBJECTIVES : I . Determine response rate preoperative induction paclitaxel/cisplatin follow concurrent paclitaxel/cisplatin radiotherapy locally advanced esophageal cancer . II . Determine toxic effect , include surgical morbidity mortality , patient survival combination therapy . III . Monitor quality life patient receive combination therapy . IV . Determine c Jun oncogene thymidylate synthase expression p53 mutation combination therapy . OUTLINE : This open label , multicenter study . ( Adenocarcinoma stratum close ) Patients receive induction chemotherapy consist paclitaxel IV 3 hour follow cisplatin IV day 1 22 . Patients receive radiation therapy 5 day week 6 week , along paclitaxel cisplatin 4 day week . Patients undergo surgery ( complete partial resection ) within 4-8 week completion chemoradiotherapy . Patients follow every 3 month first 2 year , every 6 month next 2 year , annually thereafter . Quality life assess first year follow . PROJECTED ACCRUAL : A maximum 25 patient accrue histology ( adenocarcinoma , squamous carcinoma ) within 18-24 month . ( Adenocarcinoma stratum close )</detailed_description>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven squamous cell carcinoma adenocarcinoma thoracic esophagus ( adenocarcinoma stratum close ) Locally advance surgically resectable ( T24 N01 M0 ) T1 N1 tumor eligible , T1 N0 tumor situ carcinoma eligible No cervical esophageal tumor No brain , pulmonary , liver , bone , lymph node ( cervical supraclavicular ) distant metastases No positive cytology pleura , pericardium , peritoneum No invasion tracheobronchial tree presence tracheoesophageal fistula PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 70100 % Life expectancy : Not specify Hematopoietic : Absolute granulocyte count least 1500/mm3 Platelet count least 150,000/mm3 Hepatic : Bilirubin great 1.5 mg/dL Renal : Creatinine great 1.5 mg/dL Calcium great 12 mg/dL Cardiovascular : No New York Heart Association class III/IV heart disease No history active angina No myocardial infarction within 6 month No history significant ventricular arrhythmia require medication No history clinically significant conduction system abnormality Pulmonary : FEV1 least 1.2 L Other : Not pregnant nursing Negative pregnancy test No serious concurrent infection uncontrolled nonmalignant medical illnesses No psychosis No clinically significant hearing loss No recurrent laryngeal nerve phrenic nerve paralysis No concurrent active malignancy except nonmelanomatous skin cancer carcinoma situ cervix Prior malignancy without evidence disease least 5 year allow PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent immunotherapy Chemotherapy : No prior chemotherapy No concurrent chemotherapy Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy No concurrent radiotherapy Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>stage II esophageal cancer</keyword>
	<keyword>stage III esophageal cancer</keyword>
	<keyword>squamous cell carcinoma esophagus</keyword>
	<keyword>adenocarcinoma esophagus</keyword>
</DOC>